LCL-161
As of the edition of 20 October 2026, LCL-161 is a small molecule: stopped in 2021; acts on BIRC2 and XIAP.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2021
- Kind
- Small molecule
- Registered trials
- 10, 1 stopped early
- Disease areas
- Cancer; Blood and lymph; Digestive system; Heart and blood vessels; Hormones; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
4 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product4 company-target rows are on route A because of LCL-161.
See the 4 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 7 | 5 | 0 | 1 |
| Phase 2 | 3 | 3 | 0 | 0 |
| All trials | 10 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Novartis | Lead sponsor of trials | 2008 to now |
| US Oncology | Lead sponsor of trials | 2014 to now |
| SCRI Development Innovations | Lead sponsor of trials | 2016 to now |